Download PDF
Semin Hear 2011; 32(3): 236-247
DOI: 10.1055/s-0031-1286618
© Thieme Medical Publishers

How Should Awareness of Ototoxicity Change the Way Medicine is Practiced?

P.K. Das-Purkayastha1 , J.A. Rutka2
  • 1Neurotology Clinical Fellow, University of Toronto, Toronto, Ontario, Canada
  • 2Department of Otolaryngology, University of Toronto, Toronto, Ontario, Canada
Further Information

Publication History

Publication Date:
23 September 2011 (online)

    Permissions and Reprints

ABSTRACT

Ototoxicity is a topic relevant not only to otolaryngologists and audiologists, but also to any physician who prescribes medications for severely unwell or malignant conditions. Many of the drugs required to treat these conditions will possess side effects that have the potential to damage the inner ear thus causing severe morbidity. Unfortunately side effects that can profoundly affect hearing and balance are not always considered when prescribing potentially ototoxic medications. Regrettably, these problems often go unnoticed until there is severe deafness or an irreversible vestibular loss. This article aims to identify the potential controversies with regards to prescribing ototoxic medications, and discusses ways that a physician may use monitoring to alter their practice.

KEYWORDS

Ototoxicity - vestibulotoxicity - cochleotoxic - monitoring - genetic susceptibility

REFERENCES

  • 1 Council G M. Good practice in prescribing medicines—guidance for doctors. 2008. Available at: http://www.gmc-uk.org/static/documents/content/Good_Practice_in_Prescribing_Medicines_0911.pdf Accessed February, 2010
    Google Scholar
  • 2 CPSO .Prescribing Practices. 2005. Available at: http://www.cpso.on.ca/policies/policies/default.aspx?ID=1848 Accessed July, 2010
    Google Scholar
  • 3 Seligmann H, Podoshin L, Ben-David J, Fradis M, Goldsher M. Drug-induced tinnitus and other hearing disorders.  Drug Saf. 1996;  14 198-212
    CrossrefPubMedGoogle Scholar
  • 4 Forge A, Schacht J. Aminoglycoside antibiotics.  Audiol Neurootol. 2000;  5 3-22
    CrossrefPubMedGoogle Scholar
  • 5 Moore R D, Smith C R, Lietman P S. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.  J Infect Dis. 1984;  149 23-30
    CrossrefPubMedGoogle Scholar
  • 6 Neu H C, Bendush C L. Ototoxicity of tobramycin: a clinical overview.  J Infect Dis. 1976;  134 (Suppl) S206-S218
    CrossrefPubMedGoogle Scholar
  • 7 Borradori C, Fawer C L, Buclin T, Calame A. Risk factors of sensorineural hearing loss in preterm infants.  Biol Neonate. 1997;  71 1-10
    PubMedGoogle Scholar
  • 8 Weatherly R A, Owens J J, Catlin F I, Mahoney D H. cis-platinum ototoxicity in children.  Laryngoscope. 1991;  101 917-924
    PubMedGoogle Scholar
  • 9 Yorgason J G, Fayad J N, Kalinec F. Understanding drug ototoxicity: molecular insights for prevention and clinical management.  Expert Opin Drug Saf. 2006;  5 383-399
    CrossrefPubMedGoogle Scholar
  • 10 Brummett R E. Ototoxicity resulting from the combined administration of potent diuretics and other agents.  Scand Audiol Suppl. 1981;  14 (Suppl) 215-224
    PubMedGoogle Scholar
  • 11 Tran Ba Huy P, Manuel C, Meulemans A, Sterkers O, Wassef M, Amiel C. Ethacrynic acid facilitates gentamicin entry into endolymph of the rat.  Hear Res. 1983;  11 191-202
    CrossrefPubMedGoogle Scholar
  • 12 Conlon B J, McSwain S D, Smith D W. Topical gentamicin and ethacrynic acid: effects on cochlear function.  Laryngoscope. 1998;  108 1087-1089
    CrossrefPubMedGoogle Scholar
  • 13 Munckhof W J, Grayson M L, Turnidge J D. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses.  J Antimicrob Chemother. 1996;  37 645-663
    CrossrefPubMedGoogle Scholar
  • 14 Hatala R, Dinh T, Cook D J. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis.  Ann Intern Med. 1996;  124 717-725
    PubMedGoogle Scholar
  • 15 Bailey T C, Little J R, Littenberg B, Reichley R M, Dunagan W C. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.  Clin Infect Dis. 1997;  24 786-795
    CrossrefPubMedGoogle Scholar
  • 16 Ali M Z, Goetz M B. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides.  Clin Infect Dis. 1997;  24 796-809
    CrossrefPubMedGoogle Scholar
  • 17 Barza M, Ioannidis J P, Cappelleri J C, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis.  BMJ. 1996;  312 338-345
    CrossrefPubMedGoogle Scholar
  • 18 Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis.  Am J Health Syst Pharm. 1996;  53 1141-1150
    PubMedGoogle Scholar
  • 19 Galløe A M, Graudal N, Christensen H R, Kampmann J P. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety.  Eur J Clin Pharmacol. 1995;  48 39-43
    PubMedGoogle Scholar
  • 20 Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs.  J Clin Invest. 1986;  77 1492-1500
    CrossrefPubMedGoogle Scholar
  • 21 Becvarovski Z, Michaelides E M, Kartush J M, Bojrab D I, LaRouere M J. Rapid elevation of gentamicin levels in the human labyrinth following intravenous administration.  Laryngoscope. 2002;  112 (7 Pt 1) 1163-1165
    CrossrefPubMedGoogle Scholar
  • 22 Knutson J F, Murray K T, Husarek S et al.. Psychological change over 54 months of cochlear implant use.  Ear Hear. 1998;  19 191-201
    CrossrefPubMedGoogle Scholar
  • 23 Hugues F C, Laccourreye A, Lasserre M H, Toupet M. Cochlear toxicity of erythromycin in elderly patients.  Therapie. 1984;  39 591-594
    PubMedGoogle Scholar
  • 24 Kotecha B, Richardson G P. Ototoxicity in vitro: effects of neomycin, gentamicin, dihydrostreptomycin, amikacin, spectinomycin, neamine, spermine and poly-L-lysine.  Hear Res. 1994;  73 173-184
    CrossrefPubMedGoogle Scholar
  • 25 Richardson G P, Russell I J. Cochlear cultures as a model system for studying aminoglycoside induced ototoxicity.  Hear Res. 1991;  53 293-311
    CrossrefPubMedGoogle Scholar
  • 26 McGhan L J, Merchant S N. Erythromycin ototoxicity.  Otol Neurotol. 2003;  24 701-702
    CrossrefPubMedGoogle Scholar
  • 27 Swanson D J, Sung R J, Fine M J, Orloff J J, Chu S Y, Yu V L. Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia.  Am J Med. 1992;  92 61-68
    CrossrefPubMedGoogle Scholar
  • 28 Tange R A, Dreschler W A, Claessen F A, Perenboom R M. Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparum infection.  Auris Nasus Larynx. 1997;  24 131-136
    CrossrefPubMedGoogle Scholar
  • 29 Puel J L, Bobbin R P, Fallon M. Salicylate, mefenamate, meclofenamate, and quinine on cochlear potentials.  Otolaryngol Head Neck Surg. 1990;  102 66-73
    PubMedGoogle Scholar
  • 30 Karlsson K K, Flock A. Quinine causes isolated outer hair cells to change length.  Neurosci Lett. 1990;  116 101-105
    CrossrefPubMedGoogle Scholar
  • 31 Zheng J, Ren T, Parthasarathi A, Nuttall A L. Quinine-induced alterations of electrically evoked otoacoustic emissions and cochlear potentials in guinea pigs.  Hear Res. 2001;  154 124-134
    CrossrefPubMedGoogle Scholar
  • 32 Dieler R, Shehata-Dieler W E, Brownell W E. Concomitant salicylate-induced alterations of outer hair cell subsurface cisternae and electromotility.  J Neurocytol. 1991;  20 637-653
    CrossrefPubMedGoogle Scholar
  • 33 Cazals Y. Auditory sensori-neural alterations induced by salicylate.  Prog Neurobiol. 2000;  62 583-631
    CrossrefPubMedGoogle Scholar
  • 34 Peng B G, Chen S, Lin X. Aspirin selectively augmented N-methyl-D-aspartate types of glutamate responses in cultured spiral ganglion neurons of mice.  Neurosci Lett. 2003;  343 21-24
    CrossrefPubMedGoogle Scholar
  • 35 Ding D, McFadden S L, Woo J M, Salvi R J. Ethacrynic acid rapidly and selectively abolishes blood flow in vessels supplying the lateral wall of the cochlea.  Hear Res. 2002;  173 1-9
    CrossrefPubMedGoogle Scholar
  • 36 Hinojosa R, Riggs L C, Strauss M, Matz G J. Temporal bone histopathology of cisplatin ototoxicity.  Am J Otol. 1995;  16 731-740
    PubMedGoogle Scholar
  • 37 McAlpine D, Johnstone B M. The ototoxic mechanism of cisplatin.  Hear Res. 1990;  47 191-203
    CrossrefPubMedGoogle Scholar
  • 38 Wake M, Takeno S, Ibrahim D, Harrison R, Mount R. Carboplatin ototoxicity: an animal model.  J Laryngol Otol. 1993;  107 585-589
    CrossrefPubMedGoogle Scholar
  • 39 Takeno S, Harrison R V, Ibrahim D, Wake M, Mount R J. Cochlear function after selective inner hair cell degeneration induced by carboplatin.  Hear Res. 1994;  75 93-102
    CrossrefPubMedGoogle Scholar
  • 40 Wake M, Takeno S, Ibrahim D, Harrison R. Selective inner hair cell ototoxicity induced by carboplatin.  Laryngoscope. 1994;  104 488-493
    PubMedGoogle Scholar
  • 41 Takeno S, Harrison R V, Mount R J, Wake M, Harada Y. Induction of selective inner hair cell damage by carboplatin.  Scanning Microsc. 1994;  8 97-106
    PubMedGoogle Scholar
  • 42 Konigsmark B W, Gorlin R J. Genetic and Metabolic Deafness. Philadelphia, PA: Saunders; 1976
    Google Scholar
  • 43 Tsuiki T, Murai S. Familial incidence of streptomycin hearing loss and hereditary weakness of the cochlea.  Audiology. 1971;  10 315-322
    CrossrefPubMedGoogle Scholar
  • 44 Hu D N, Qui W Q, Wu B T et al.. Genetic aspects of antibiotic induced deafness: mitochondrial inheritance.  J Med Genet. 1991;  28 79-83
    CrossrefPubMedGoogle Scholar
  • 45 Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity.  Ann N Y Acad Sci. 1999;  884 99-109
    CrossrefPubMedGoogle Scholar
  • 46 Braverman I, Jaber L, Levi H et al.. Audiovestibular findings in patients with deafness caused by a mitochondrial susceptibility mutation and precipitated by an inherited nuclear mutation or aminoglycosides.  Arch Otolaryngol Head Neck Surg. 1996;  122 1001-1004
    CrossrefPubMedGoogle Scholar
  • 47 Roth S M, Williams S M, Jiang L, Menon K S, Jeka J J. Susceptibility genes for gentamicin-induced vestibular dysfunction.  J Vestib Res. 2008;  18 59-68
    PubMedGoogle Scholar
  • 48 Li Y, Womer R B, Silber J H. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.  Eur J Cancer. 2004;  40 2445-2451
    CrossrefPubMedGoogle Scholar
  • 49 Coradini P P, Cigana L, Selistre S G, Rosito L S, Brunetto A L. Ototoxicity from cisplatin therapy in childhood cancer.  J Pediatr Hematol Oncol. 2007;  29 355-360
    CrossrefPubMedGoogle Scholar
  • 50 Knight K R, Kraemer D F, Neuwelt E A. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.  J Clin Oncol. 2005;  23 8588-8596
    CrossrefPubMedGoogle Scholar
  • 51 Kushner B H, Budnick A, Kramer K, Modak S, Cheung N K. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.  Cancer. 2006;  107 417-422
    CrossrefPubMedGoogle Scholar
  • 52 Blakley B W, Gupta A K, Myers S F, Schwan S. Risk factors for ototoxicity due to cisplatin.  Arch Otolaryngol Head Neck Surg. 1994;  120 541-546
    CrossrefPubMedGoogle Scholar
  • 53 Bess F H, Dodd-Murphy J, Parker R A. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status.  Ear Hear. 1998;  19 339-354
    CrossrefPubMedGoogle Scholar
  • 54 Ross C J, Katzov-Eckert H, Dubé M P CPNDS Consortium et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.  Nat Genet. 2009;  41 1345-1349
    CrossrefPubMedGoogle Scholar
  • 55 Rourke T. Aminoglycoside ototoxicity: how practical is this genetic screening test?.  BMJ. 2007;  335 952
    PubMedGoogle Scholar
  • 56 Campbell K CM. Audiologic monitoring for ototoxicity. In: Roland P S, Rutka J A, eds. Ototoxicity. Hamilton, Ontario, Canada: BC Decker Inc.; 2004
    Google Scholar
  • 57 Burger T, Spahn C, Richter B, Eissele S, Löhle E, Bengel J. Psychic stress and quality of life in parents during decisive phases in the therapy of their hearing-impaired children.  Ear Hear. 2006;  27 313-320
    CrossrefPubMedGoogle Scholar
  • 58 Mulrow C D, Aguilar C, Endicott J E et al.. Quality-of-life changes and hearing impairment. A randomized trial.  Ann Intern Med. 1990;  113 188-194
    PubMedGoogle Scholar
  • 59 Hallberg L R, Ringdahl A. Living with cochlear implants: experiences of 17 adult patients in Sweden.  Int J Audiol. 2004;  43 115-121
    CrossrefPubMedGoogle Scholar
  • 60 Arlinger S. Negative consequences of uncorrected hearing loss—a review.  Int J Audiol. 2003;  42 (Suppl 2) S17-S20
    CrossrefPubMedGoogle Scholar
  • 61 Eisenberg L S. Use of the cochlear implant by the prelingually deaf.  Ann Otol Rhinol Laryngol Suppl. 1982;  91 (2 Pt 3) 62-66
    PubMedGoogle Scholar
  • 62 Fellinger J, Holzinger D, Dobner U et al.. Mental distress and quality of life in a deaf population.  Soc Psychiatry Psychiatr Epidemiol. 2005;  40 737-742
    CrossrefPubMedGoogle Scholar
  • 63 Spahn C, Burger T, Löschmann C, Richter B. Quality of life and psychological distress in parents of children with a cochlear implant.  Cochlear Implants Int. 2004;  5 13-27
    CrossrefPubMedGoogle Scholar
  • 64 Hogan A, Hawthorne G, Kethel L et al.. Health-related quality-of-life outcomes from adult cochlear implantation: a cross-sectional survey.  Cochlear Implants Int. 2001;  2 115-128
    CrossrefPubMedGoogle Scholar
  • 65 Wake M, Hughes E K, Collins C M, Poulakis Z. Parent-reported health-related quality of life in children with congenital hearing loss: a population study.  Ambul Pediatr. 2004;  4 411-417
    CrossrefPubMedGoogle Scholar
  • 66 Jerger J F, Carhart R, Tillman T W, Peterson J L. Some relations between normal hearing for pure tones and for speech.  J Speech Hear Res. 1959;  2 126-140
    PubMedGoogle Scholar
  • 67 American Speech-Language-Hearing Association . Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy.  ASHA. 1994;  36 (Suppl 12) 11-19
    PubMedGoogle Scholar
  • 68 Campbell K. Ototoxicity: understanding oxidative mechanisms.  J Am Acad Audiol. 2003;  14 121-123
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 Fausti S A, Larson V D, Noffsinger D, Wilson R H, Phillips D S, Fowler C G. High-frequency audiometric monitoring strategies for early detection of ototoxicity.  Ear Hear. 1994;  15 232-239
    CrossrefPubMedGoogle Scholar
  • 70 Ress B D, Sridhar K S, Balkany T J, Waxman G M, Stagner B B, Lonsbury-Martin B L. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Third place—Resident Clinical Science Award 1998.  Otolaryngol Head Neck Surg. 1999;  121 693-701
    CrossrefPubMedGoogle Scholar
  • 71 Sha S H, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals.  Hear Res. 2001;  155 1-8
    CrossrefPubMedGoogle Scholar
  • 72 Wright D E, Drouin P. Cisplatin-induced myasthenic syndrome.  Clin Pharm. 1982;  1 76-78
    PubMedGoogle Scholar
  • 73 Gorga M P, Neely S T, Bergman B et al.. Otoacoustic emissions from normal-hearing and hearing-impaired subjects: distortion product responses.  J Acoust Soc Am. 1993;  93 (4 Pt 1) 2050-2060
    CrossrefPubMedGoogle Scholar
  • 74 Rybak L P, Whitworth C A. Ototoxicity: therapeutic opportunities.  Drug Discov Today. 2005;  10 1313-1321
    CrossrefPubMedGoogle Scholar
  • 75 Beattie R C, Kenworthy O T, Luna C A. Immediate and short-term reliability of distortion-product otoacoustic emissions.  Int J Audiol. 2003;  42 348-354
    CrossrefPubMedGoogle Scholar
  • 76 Knight K R, Kraemer D F, Winter C, Neuwelt E A. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.  J Clin Oncol. 2007;  25 1190-1195
    CrossrefPubMedGoogle Scholar
  • 77 Halmagyi G M, Curthoys I S. A clinical sign of canal paresis.  Arch Neurol. 1988;  45 737-739
    CrossrefPubMedGoogle Scholar
  • 78 Halmagyi M, Curthoys I S, Aw S T. The human vestibulo-ocular reflex after unilateral vestibular differentiation. The results of high acceleration impulsive testing. In: Sharpe J, Barber H O, eds. The Vestibulo-Ocular Reflex and Vertigo. New York, NY: Raven Press; 1993: 45-54
    Google Scholar
  • 79 Chambers B R, Mai M, Barber H O. Bilateral vestibular loss, oscillopsia, and the cervico-ocular reflex.  Otolaryngol Head Neck Surg. 1985;  93 403-407
    PubMedGoogle Scholar
  • 80 Coats A C, Smith S Y. Body position and the intensity of caloric nystagmus.  Acta Otolaryngol. 1967;  63 515-532
    PubMedGoogle Scholar
  • 81 Fee Jr W E. Aminoglycoside ototoxicity in the human.  Laryngoscope. 1980;  90 (10 Pt 2, Suppl 24) 1-19
    PubMedGoogle Scholar
  • 82 Tomlinson R D, Saunders G E, Schwarz D W. Analysis of human vestibulo-ocular reflex during active head movements.  Acta Otolaryngol. 1980;  90 184-190
    CrossrefPubMedGoogle Scholar
  • 83 Van De Water T R, Rybak L P. Ototoxic damage to hearing: Otoprotective Therapies. In: Roland P S, Rutka J A, eds. Ototoxicity. Hamilton, Ontario, Canada: BC Decker Inc.; 2004
    Google Scholar
  • 84 Gallagher T H, Waterman A D, Ebers A G, Fraser V J, Levinson W. Patients' and physicians' attitudes regarding the disclosure of medical errors.  JAMA. 2003;  289 1001-1007
    CrossrefPubMedGoogle Scholar
  • 85 Hébert P C, Levin A V, Robertson G. Bioethics for clinicians: 23. Disclosure of medical error.  CMAJ. 2001;  164 509-513
    PubMedGoogle Scholar
  • 86 Song B B, Anderson D J, Schacht J. Protection from gentamicin ototoxicity by iron chelators in guinea pig in vivo.  J Pharmacol Exp Ther. 1997;  282 369-377
    PubMedGoogle Scholar
  • 87 Schacht J. Antioxidant therapy attenuates aminoglycoside-induced hearing loss.  Ann N Y Acad Sci. 1999;  884 125-130
    PubMedGoogle Scholar
  • 88 Chen Y, Huang W G, Zha D J et al.. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic.  Hear Res. 2007;  226 178-182
    CrossrefPubMedGoogle Scholar
  • 89 Fouladi M, Chintagumpala M, Ashley D et al.. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.  J Clin Oncol. 2008;  26 3749-3755
    CrossrefPubMedGoogle Scholar

J.A. RutkaM.D. F.R.C.S.C. 

Toronto General Hospital, Eaton Wing 8N-873

200 Elizabeth Street, Toronto, ON M5G 2C4

Email: John.Rutka@uhn.on.ca

      >